Thermedical, a privately held company developing proprietary thermal therapy equipment for numerous clinical conditions, today announced that it closed $1.5 million in Series A funding with a private investor, Samuel H. Maslak, Sc.D. The financing will fund continued research and development, and additional patent filings; it will also help the company achieve 510(k) regulatory clearance from the U.S. Food & Drug Administration (FDA).
Thermedical is developing preclinical prototypes for a Saline-Enhanced Radio Frequency (SERF™) ablation system for treating malignant solid tissue, such as liver cancer, and for difficult-to-treat cardiac arrhythmias, such as ventricular tachycardia (VT).
"I am investing in Thermedical and joining its Board of Directors because I believe the SERF Ablation Technology will dramatically improve the efficacy of ablation therapy," said Dr. Maslak, chairman of the board of directors at Thermedical. "I project that this revolutionary technology will alter the course of treatment for patients with liver cancer and other solid tumors, and that it will deliver a cost-effective cure for VT.
"It's clear to me that Thermedical will become an important, highly profitable company developing and selling thermal therapies. Simply put, SERF Ablation Technology will be a game-changer in both cancer and VT treatment."
Breast cancer survivors at higher risk of developing second cancers